Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Abstract Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13223-019-0366-x |